Nanoparticles/rss/search.php?qu=nanopart/rss/search.php?qu=nanoparticles/rss/search.php?qu=nanoparticles RSS Page 16

Filtered By:
Infectious Disease: Hepatitis C

This page shows you your search results in order of date. This is page number 16.

Order by Relevance | Date

Total 11868 results found since Jan 2013.

Stability of a diffusive-delayed HCV infection model with general cell-to-cell incidence function incorporating immune response and cell proliferation
Theory Biosci. 2023 Jul 12. doi: 10.1007/s12064-023-00395-z. Online ahead of print.ABSTRACTIn this work, we analyse the dynamics of a five-dimensional hepatitis C virus infection mathematical model including the spatial mobility of hepatitis C virus particles, the transmission of hepatitis C virus infection by mitosis process of infected hepatocytes with logistic growth, time delays, antibody response and cytotoxic T lymphocyte (CTL) immune response with general incidence functions for both modes of infection transmission, namely virus-to-cell as well as cell-to-cell. Firstly, we prove rigorously the existence, the uniquen...
Source: Theory in Biosciences - July 12, 2023 Category: Biology Authors: Alexis Nangue Yanick Junior Tchuimeni Source Type: research

Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study
CONCLUSION: Treatment with sofosbuvir-velpatasvir or sofosbuvir-velpatasvir-voxilaprevir was safe and resulted in high SVR12 rates in Korean HCV patients.PMID:37424500 | DOI:10.3904/kjim.2022.252
Source: The Korean Journal of Internal Medicine - July 10, 2023 Category: Internal Medicine Authors: Jeong Heo Yoon Jun Kim Sung Wook Lee Youn-Jae Lee Ki Tae Yoon Kwan Soo Byun Yong Jin Jung Won Young Tak Sook-Hyang Jeong Kyung Min Kwon Vithika Suri Peiwen Wu Byoung Kuk Jang Byung Seok Lee Ju-Yeon Cho Jeong Won Jang Soo Hyun Yang Seung Woon Paik Hyung Jo Source Type: research

Sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir: novel treatment options for na ïve and previously treated hepatitis C infection
Korean J Intern Med. 2023 Jul;38(4):454-455. doi: 10.3904/kjim.2023.248. Epub 2023 Jun 30.NO ABSTRACTPMID:37424499 | DOI:10.3904/kjim.2023.248
Source: The Korean Journal of Internal Medicine - July 10, 2023 Category: Internal Medicine Authors: Hyun Phil Shin Source Type: research

Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study
CONCLUSION: Treatment with sofosbuvir-velpatasvir or sofosbuvir-velpatasvir-voxilaprevir was safe and resulted in high SVR12 rates in Korean HCV patients.PMID:37424500 | PMC:PMC10338242 | DOI:10.3904/kjim.2022.252
Source: The Korean Journal of Internal Medicine - July 10, 2023 Category: Internal Medicine Authors: Jeong Heo Yoon Jun Kim Sung Wook Lee Youn-Jae Lee Ki Tae Yoon Kwan Soo Byun Yong Jin Jung Won Young Tak Sook-Hyang Jeong Kyung Min Kwon Vithika Suri Peiwen Wu Byoung Kuk Jang Byung Seok Lee Ju-Yeon Cho Jeong Won Jang Soo Hyun Yang Seung Woon Paik Hyung Jo Source Type: research

Inhibitors Targeting Hepatitis C Virus (HCV) Entry
Mini Rev Med Chem. 2023;23(11):1193-1221. doi: 10.2174/1389557522666220428115152.ABSTRACTInfections caused by the Hepatitis C virus (HCV) affect around 70 million people worldwide, leading to serious liver problems, such as fibrosis, steatosis, and cirrhosis, in addition to progressing to hepatocellular carcinoma and becoming globally the main cause of liver disease. Despite great therapeutic advances in obtaining pan-genotypic direct-acting antivirals (DAAs), around 5-10% of affected individuals are unable to eliminate the virus by their own immune system's activity. Still, there are no licensed vaccines so far. In this c...
Source: Mini Reviews in Medicinal Chemistry - July 10, 2023 Category: Chemistry Authors: Paulo Fernando da Silva Santos-J únior Jo ão Xavier de Araújo-Júnior Edeildo Ferreira da Silva-J únior Source Type: research

Clinical characteristics and outcomes of infection with human T-lymphotropic virus in a non-endemic area: a single institution study
CONCLUSION: HTLV-seropositivity was not associated with increased 1 year mortality in multivariate analysis. However, our study is limited by our small patient sample size, as well as the biased patient control population due to selection factors for HTLV testing.PMID:37426028 | PMC:PMC10324566 | DOI:10.3389/fmicb.2023.1187697
Source: Cancer Control - July 10, 2023 Category: Cancer & Oncology Authors: Margery Gang Feng Gao Sneha Poondru Theodore Thomas Lee Ratner Source Type: research

Providing Hepatitis C Treatment Locally for Substance-Using Patients
J Prim Care Community Health. 2023 Jan-Dec;14:21501319231186355. doi: 10.1177/21501319231186355.ABSTRACTThis quality improvement (QI) project provided Hepatitis C virus (HCV) treatment at a Federally Qualified Health Clinic (FQHC) for persons who use illicit drugs. Many of these individuals sought treatment at the local Infectious Disease (ID) clinic but were denied care as they require a patient be drug-free for 6 months prior to HCV treatment. These individuals expressed a desire to be cured of HCV, which can lead to liver failure or cirrhosis if left untreated. This project bridged the existing gap in HCV treatment that...
Source: Primary Care - July 10, 2023 Category: Primary Care Authors: Susan B Clapp Christopher B Johnson Source Type: research

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20